Shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) shot up 2.9% on Friday . The company traded as high as $10.49 and last traded at $10.49, with a volume of 696,079 shares traded. The stock had previously closed at $10.19.

The firm has a 50 day moving average price of $11.02 and a 200 day moving average price of $11.64. The firm has a market capitalization of $523.86 million and a PE ratio of 14.16.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share for the quarter. The business had revenue of $39 million for the quarter, compared to analyst estimates of $37.90 million. On average, equities analysts forecast that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current year.

In other news, CFO Wilson Wai-Shun Cheung sold 7,802 shares of SciClone Pharmaceuticals stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $10.62, for a total transaction of $82,857.24. Following the sale, the chief financial officer now owns 25,000 shares in the company, valued at $265,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Friedhelm Blobel sold 501,875 shares of SciClone Pharmaceuticals stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $10.00, for a total transaction of $5,018,750.00. Following the sale, the chief executive officer now owns 588,255 shares in the company, valued at approximately $5,882,550. The disclosure for this sale can be found here.

An institutional investor recently raised its position in SciClone Pharmaceuticals stock. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 12.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 232,900 shares of the specialty pharmaceutical company’s stock after buying an additional 25,225 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.47% of SciClone Pharmaceuticals worth $2,143,000 as of its most recent SEC filing.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.